

Data + Perspectives: Investigators Discuss the Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with Hematologic Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What are the targets of the novel bispecific antibodies glofitamab, epcoritamab and mosunetuzumab in patients with lymphoma?
 - a. CD20 x CD3
 - b. CD20 x CD8
 - c. CD19 x CD3
 - d. CD78 x CD3

2. The bispecific antibodies talquetamab, teclistamab and cevostamab have which of the following targets in common?
 - a. BCMA
 - b. CD3
 - c. FcRH5
 - d. GPRC5

3. The ZUMA-7 trial demonstrated a significant improvement in which of the following metrics with second-line axicabtagene ciloleucel treatment for relapsed/refractory (R/R) large B-cell lymphoma?
 - a. Improvement in objective response rate
 - b. Improvement in event-free survival
 - c. Improvement in median overall survival
 - d. Both A and B
 - e. A, B, and C
 - f. None of the above

4. Which of the following best describes the severity of cytokine release syndrome (CRS) observed in patients with R/R follicular lymphoma receiving mosunetuzumab monotherapy in Phase I/II investigation?
 - a. Most events were Grade 1
 - b. Most events were Grade 2
 - c. Most events were Grade 3
 - d. Most events were Grade 4
 - e. CRS was not observed with mosunetuzumab monotherapy

5. Which of the following best describes clinical observations of idecabtagene vicleucel in older patients with multiple myeloma compared to the overall population?
 - a. Responses are similar, but toxicity is significantly increased for patients over 65
 - b. Toxicity is similar, but response is significantly diminished in patients over 65
 - c. Responses and toxicity are similar in patients over 65 and the overall population